Becton Dickinson to merge diagnostic units
This article was originally published in Clinica
Becton Dickinson is to consolidate three of its subsidiary companies to form a single bioscience/diagnostics business. The move should be completed by January 1999. Clateo Castellini, Becton's CEO, chairman and president, said: "The in vitro diagnostic industry is rapidly changing, the clinical laboratory market is consolidating, and our customers are creating larger, more automated laboratories. We believe this new structure gives us the scope and reach to capitalise on new opportunities."
You may also be interested in...
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.